An intramuscular administration of Zofran for postoperative nausea and vomiting in adults has been approved by the FDA. Normally, Zofran is given through an IV injection or in tablet form. This new intramuscular (IM) administration bypasses difficulties some patients may encounter. For example, some patients have difficulty swallowing, have small veins, or have veins that won't allow an IV to enter.
While IM administration has been approved in adults, it has not gained clearance for use in children.
Negative side effects have been noted in postoperative clinical tests The most common are dizziness, headache, drowsiness, sedation, and constipation. Other adverse effects are diarrhea, dry mouth, and skin rash.
The Zofran drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.